ReviewTranslational lung cancer research2017
Blood-based biomarkers in lung cancer: prognosis and treatment decisions.
Review in Translational lung cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 45 citations in OpenAlex.
- Predictive Value of EGFR Expression for the Efficacy of Near-Infrared Photoimmunotherapy in Head and Neck Cancer.JMA journal · 2026Article
- The Role of ctDNA for Diagnosis and Histological Prediction in Early Stage Non-Small-Cell Lung Cancer: A Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
- Therapeutic drug monitoring of immune checkpoint inhibitors: based on their pharmacokinetic properties and biomarkers.Cancer chemotherapy and pharmacology · 2023Review
- Midazolam impedes lung carcinoma cell proliferation and migration via EGFR/MEK/ERK signaling pathway.Open medicine (Warsaw, Poland) · 2023Article
- Systemic inflammatory biomarkers in primary central nervous system lymphoma versus high-grade glioma: exploratory, comparative and correlative analysis.CNS oncology · 2022Article
- MicroRNA-200a-3p and GATA6 are abnormally expressed in patients with non-small cell lung cancer and exhibit high clinical diagnostic efficacy.Experimental and therapeutic medicine · 2022Article
- Prognostic significance of a complement factor H autoantibody in early stage NSCLC.Cancer biomarkers : section A of Disease markers · 2022Article
- Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis.American journal of respiratory and critical care medicine · 2021Article
- Toward Personalized Radiation Therapy of Liver Metastasis: Importance of Serial Blood Biomarkers.JCO clinical cancer informatics · 2021Article
- NORAD regulates epithelial‑mesenchymal transition of non‑small cell lung cancer cells via miR‑422a.Molecular medicine reports · 2021Article
- Circulating tumor cells can predict the prognosis of patients with non-small cell lung cancer after resection: a retrospective study.Translational lung cancer research · 2021Article
- LncRNA PRRT3-AS1 exerts oncogenic effects on nonsmall cell lung cancer by targeting microRNA-507/homeobox B5 axis.Oncology research · 2021Article
- Review
- Blood-based Biomarkers for Early Diagnosis of Lung Cancer: A Review Article.JNMA; journal of the Nepal Medical Association · 2020Review
- Circulating microRNA-590-5p functions as a liquid biopsy marker in non-small cell lung cancer.Cancer science · 2020Article
- Selected Tumour Biomarker Levels in Sheep with Pulmonary Adenomatosis.Journal of veterinary research · 2020Article
- A nomogram to predict outcomes of lung cancer patients after pneumonectomy based on 47 indicators.Cancer medicine · 2020Article
- Clinical relevance of mutant-allele tumor heterogeneity and lung adenocarcinoma.Annals of translational medicine · 2019Article
- Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis.Cancer reports (Hoboken, N.J.) · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Despite recent advances, non-small cell lung cancer (NSCLC) remains a devastating disease with overall poor prognosis. Major contributing factors include obstacles to diagnosing the disease early in its course during the asymptomatic stage as well as diversity and complexity of its biology underlying tumorigenesis and tumor progression. Advances in molecularly targeted therapies which drives the development of personalized cancer care require precise and comprehensive understanding of tumor biology, not only at the time of diagnosis but also during treatment course and surveillance. As lung tumor tissue can be difficult to obtain without invasive and potentially risky procedures, it is difficult to monitor treatment response with serial tissue biopsies. Development of non-invasive but reliable blood based tumor markers has become an important research area. In this review, we focus on the following circulating biomarkers that have been identified in recent years: circulating tumor cells (CTCs); circulating cell-free nucleic acids, such as circulating tumor DNA (ctDNA) and microRNA (miR); and other biomarkers such as genomic and proteomic features. These biomarkers not only have prognostic values, but also can help guild treatment decisions by monitoring tumor burden, detecting minimal residual disease and/or recurrent disease, as well as monitoring evolution of genetic alterations throughout the treatment course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.